Benzoquinone ansamycins

Anticancer Agents from Natural Products

Volumn , Issue , 2005, Pages 339-356

  Snader, Kenneth M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BIOCHEMISTRY; NAPHTHALENE;

ANTI-CANCER AGENTS; AROMATIC RINGS; BENZOQUINONES; CYCLIC MOLECULES; GELDANAMYCIN; LONG ALIPHATIC CHAIN; NAPHTHALENE RING; POTENTIAL UTILITY;

AROMATIZATION;

EID: 33646053096     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (57)

1. Lancini, G. and Parenti, F., Antibiotics: An Integrated View, Springer, New York, 1982, 10.
2. DeBoer, C. et al., Geldanamycin, a new antibiotic, J. Antibiot., 23, 442, 1970.
3. Rinehart, K.L. et al., Geldanamycin I. Structure assignment, J. Am. Chem. Soc., 92, 7591, 1970.
4. Whitesell L. et al., Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation, Proc. Natl. Acad. Sci. USA, 91, 8324, 1994.
5. Schnur, R.C. and Corman, M.L., Tandem [3,3]-sigmatropic rearrangements in an ansamycin: Stereospecific conversion of an (S)-allylic alcohol to an (S)-allylic amine derivative, J. Org. Chem., 59, 2581, 1994.
6. Supko, J.G. et al., Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent, Cancer Chemother. Pharmacol., 36, 305, 1995.
7. Omura, S. et al., Herbimycin, a new antibiotic produced by a strain of Streptomyces, J. Antibiot., 32, 255, 1979.
8. Furusaki, A. et al., Herbimycin A: an ansamycin antibiotic; x-ray crystal structure, J. Antibiot., 33, 781, 1980.
9. Fukazawa, H. et al., Specific inhibition of cytoplasmic protein tyrokinases by herbimycin A in vitro, Biochem. Pharmacol., 42, 1661, 1991.
10. Tanida, S., Hasegawa, T., and Higashida, E. Macbecins I and II, new antitumor antibiotics. I., J. Antibiot., 33, 199, 1980.
11. Muroi, M. et al., Macbecins I and II, new antitumor antibiotics. II., J. Antibiot., 33, 205, 1980.
12. Shibata, K. et al., TAN420 Antibiotics, J. Antib., 39, 1630, 1986.
13. Miller, P. et al., Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins, Cancer Res. 54, 2724, 1994.
14. Miller, P. et al., Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185, Biochem. Biophys. Res. Comm., 210, 1313, 1994.
15. Sepp-Lorenzino, L. et al., Herbimycin A induces the 20S proteasome and ubiquitin dependent degradation of receptor tyrosine kinases, J. Biol. Chem., 270, 16580, 1995.
16. Li, L.H. et al., Effects of geldanamycin and its derivatives on RNA-directed DNA polymerase and infectivity of Rausher leukemia virus, Cancer Treat. Rep., 61, 815, 1977.
17. Conde, A.G., et al., Induction of heat shock proteins by tryosine kinase inhibitors in rat cardiomylocytes and myogenic cells confers protection against simulated ischemia, J. Mol. Cell Cardiol., 29, 1927, 1997.
18. Kumar, R., Musiyenko, A., and Barik, S., The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin, Malaria J., 2, 1, 2003.
19. Benchekroun, N.M., Myers, C.E., and Sinha, B.K., Free radical formation by ansamycin benzoquinone in human breast tumor cells; implications for cytotoxicity and resistance, Free Radic. Biol. Med., 17, 191, 1994.
20. Neckers, L., Schulte, T.W., and Mimnaugh, E., Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity, Investig. New Drugs, 17, 361, 1999.
21. Ferarini, M. et al., Unusual expression and localization of heat-shock proteins in human tumor cells, Int. J. Cancer, 51, 613, 1992.
22. Ochel, H-J., Eichhorn, K., and Gademann, G., Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones, Cell Stress Chaperones, 6, 105, 2001.
23. Uehara, Y., et al., Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus, Mol. Cell Biol., 6, 2198, 1986.
24. Uehara, Y. et al., Effects of herbimycin derivatives on src oncogene function in relation to antitumor activity, J. Antibiot. (Tokyo), 41, 831, 1988.
25. Stebbins, C.E. et al., Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent, Cell, 89, 239, 1997.
26. Bergerat, A. et al., An atypical topoisomerase II from Archaea with implications for meiotic recombination, Nature, 386, 414, 1997.
27. Grenert et al., The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation, J. Biol. Chem. 272, 23843, 1997.
28. Schulte, T.W. et al., Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin, Cell Stress Chaperones, 3, 100, 1998.
29. Sharma, S.V., Agatsuma, T., and Nakano, H., Targeting of the protein Hsp90 by the transformation suppressing agent radicicol, Oncogene, 16, 2639, 1998.
30. Roe, S.M. et al., Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin, J. Med. Chem., 42, 260, 1999.
31. Chiosis, G. et al., A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells, Chem. Biol., 8, 289, 2001.
32. Chiosis, G., Rosen, N., and Sepp-Kirenzino, L., LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family, Bioorg. Med. Chem. Lett., 11, 909, 2001.
33. Baker, R and Castro, L., Total synthesis of (+)-macbecin I, J. Chem. Soc., Perkin Trans. I. 47, 1990.
34. Evans, D.A. et al., Asymmetric synthesis of macbecin I, J. Org. Chem., 57, 1067, 1992.
35. Panek, J.S. and Xu, F., Total synthesis of (+)-macbecin I, J. Am. Chem. Soc., 117, 10587, 1995.
36. Martin, S.F. et al., A formal total synthesis of (+)-macbecin I, J. Org. Chem., 57,1070, 1992.
37. Nakata, M. et al., Total synthesis of herbimycin A, Tetrahedron Lett., 32, 6015, 1991.
38. Nakata, M. et al., The total synthesis of herbimycin-a, Bull. Chem. Soc. Jpn., 65, 2974, 1992.
39. Andrus, M.B. et al., Total synthesis of (+)-geldanamycin and (-)-o-quinogeldanamycin with use of asymmetric anti-and syn-glycolate aldol reactions, Org. Lett., 4, 3549, 2002.
40. Evans, D.A., Miller, S.J. and Ennis, M.D., Asymmetric synthesis of the benzoquinoid ansamycin antitumor antibiotics: Total synthesis of (+)-macbecin, J. Org. Chem., 58, 471, 1993.
41. Panek, J.S., Xu, F., and Rondon, A.C., Chiral crotylsilane-based approach to benzoquinoid ansamycins: Total synthesis of (+)-Mabecin I, J. Am. Chem. Soc., 120, 4113, 1998.
42. Andrus, M.B. et al., Total synthesis of (+)-geldanamycin and (-)-quinogeldanamycin: asymmetric glycolate aldol reactions and biological evaluation, J. Org. Chem., 68, 8162, 2003.
43. Andrus, M.B., Meredith, E.L., and Soma Sekhar, B.B.V., Synthesis of the left-hand portion of geldanamycin using an anti-glycolate aldol reaction, Org. Lett., 3, 259, 2001.
44. Rinehart, K.L. et al., Synthesis of phenazine and phenoxazinone derivatives of geldanamycin as potential polymerase inhibitors, Bioorg. Chem., 6, 353, 1977.
45. Schnur, R.C. et al., Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives, J. Med. Chem., 38, 3806, 1995.
46. Schnur, R.C. et al., erbB-2 Oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action and structure-activity relationships, J. Med. Chem., 38, 3813, 1995.
47. Prodromou, C. et al., Identification and structural characterization of the ATP/ADP binding site in the Hsp90 molecular chaperone, Cell, 90, 65, 1997.
48. Prodromou, C. et al., A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone, Nat. Struct. Biol, 4, 477, 1997.
49. Kudkuk, S.D. et al., Synthesis and evaluation of geldanamycin-estradiol hybrids, Bioorg. Med. Chem. Lett., 9, 1233, 1999.
50. Kudkuk, S.D. et al., Synthesis and evaluation of geldanamycin-testosterone hybrids, Bioorg. Med. Chem. Lett., 10, 1303, 2000.
51. Zheng, F.F., et al., Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases, Cancer Res., 60, 2090, 2000.
52. Sausville, E.A., Tomaszewski, J.E., and Ivy, P., Clinical development of 17-allylamino-17-demethoxygeldanamycin, Curr. Cancer Drug Targets, 3, 377, 2003.
53. A Phase I and Pharmacologic Study of 17-(Allylamino)-17-demethoxygeldanamycin (AAG, NSC 330507) in Adult Patients with Solid Tumors, NIH Clinical Research Studies, Protocol Number: 99-C-0054. Available at: http://clinicaltrials.gov.
54. Tabibi, S.E. et al., Water-insoluble drug delivery system, U.S. Patent, 6,682,758 B1, 2004.
55. Kasuya, Y. et al., Improved synthesis and evaluation of 17-substituted aminoalkylgeldanamycin derivatives applicable to drug delivery systems, Bioorg. Med. Chem. Lett., 11, 2089, 2001.
56. Dictionary of Natural Products on CD-ROM, Version 12:2. Chapman & Hall, Boca Raton, FL, 2004.
57. Martin, S.F. et al., Novel approach to the ansamycin antibiotics Macbecin I and Herbimycin A. A formal total synthesis of (+)-Macbecin I, Tetrahedron, 52, 3229, 1996.